Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps1-08-01 | Translational 1 | ETA2023

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI resistant metastatic thyroid cancers

Rehman Syed Abdul , Gorona Aakash , Nohr Erik , Kat Yuan Xiaoli , Amin Parthiv , Ghaznavi Sana , Lamb Debbie , McIntyre John , Eszlinger Markus , Paschke Ralf

Introduction: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have RAI-resistant disease, resulting in poor prognosis and high disease-related mortality. Current studies of individualized therapy with different MAPK inhibitors report restoring RAI-avidity in 50 – 70% of BRAF and RAS mutated and thyroid cancers with no detected driver mutation. Five recent case reports of rare NTRK and RET-PTC fusion-positive metast...

ea0084op-09-46 | Oral Session 9: Thyroid Cancer Clinical | ETA2022

Interim outcome analysis of prospective ATA recurrence risk (RR) stratification for postoperative treatment and follow up of differentiated thyroid cancer (DTC)

Wu Jiahui , Yang Hu Xun , Ghaznavi Sana , Kinnear Susan , Symonds Christopher , Grundy Peter , Parkins Vicky , Sharma Priyanka , Lamb Debbie , Khalil Moosa , Hyrcza Martin , Chandarana Shamir , Pasieka Janice , Harvey Adrian , Warshawski Joseph , Hart Robert , Deutschman Michael , Randall Derrick , Paschke Ralf

Objective: The 2016 ATA RR assessment recommendations for patients with DTC were based on retrospective studies. We present the first outcomes of a prospective assessment of thyroid cancer management according to the ATA RR stratification.Methods: Using the Calgary prospective thyroid cancer database, we identified 612 patients with differentiated thyroid cancer (DTC) treated at our centre between April 2017 and December 2021. Each case was reviewed by t...